266 related articles for article (PubMed ID: 28119364)
21. Fluorescently labeled therapeutic antibodies for detection of microscopic melanoma.
Day KE; Beck LN; Deep NL; Kovar J; Zinn KR; Rosenthal EL
Laryngoscope; 2013 Nov; 123(11):2681-9. PubMed ID: 23616260
[TBL] [Abstract][Full Text] [Related]
22. Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety.
Bernhard W; Barreto K; El-Sayed A; Gonzalez C; Viswas RS; Toledo D; Casaco A; DeCoteau J; Fonge H; Geyer CR
BMC Cancer; 2021 Mar; 21(1):270. PubMed ID: 33711962
[TBL] [Abstract][Full Text] [Related]
23. Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma.
Keyaerts M; Xavier C; Heemskerk J; Devoogdt N; Everaert H; Ackaert C; Vanhoeij M; Duhoux FP; Gevaert T; Simon P; Schallier D; Fontaine C; Vaneycken I; Vanhove C; De Greve J; Lamote J; Caveliers V; Lahoutte T
J Nucl Med; 2016 Jan; 57(1):27-33. PubMed ID: 26449837
[TBL] [Abstract][Full Text] [Related]
24. A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme).
Avallone A; Piccirillo MC; Aloj L; Nasti G; Delrio P; Izzo F; Di Gennaro E; Tatangelo F; Granata V; Cavalcanti E; Maiolino P; Bianco F; Aprea P; De Bellis M; Pecori B; Rosati G; Carlomagno C; Bertolini A; Gallo C; Romano C; Leone A; Caracò C; de Lutio di Castelguidone E; Daniele G; Catalano O; Botti G; Petrillo A; Romano GM; Iaffaioli VR; Lastoria S; Perrone F; Budillon A
BMC Cancer; 2016 Feb; 16():69. PubMed ID: 26857924
[TBL] [Abstract][Full Text] [Related]
25. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
[TBL] [Abstract][Full Text] [Related]
26. Quantum dots-bevacizumab complexes for in vivo imaging of tumors.
Gazouli M; Bouziotis P; Lyberopoulou A; Ikonomopoulos J; Papalois A; Anagnou NP; Efstathopoulos EP
In Vivo; 2014; 28(6):1091-5. PubMed ID: 25398804
[TBL] [Abstract][Full Text] [Related]
27. The Sentinel Margin: Intraoperative
van Keulen S; Nishio N; Birkeland A; Fakurnejad S; Martin B; Forouzanfar T; Cunanan K; Colevas AD; S van den Berg N; Rosenthal E
Clin Cancer Res; 2019 Aug; 25(15):4656-4662. PubMed ID: 31142505
[TBL] [Abstract][Full Text] [Related]
28. Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies.
Heskamp S; Boerman OC; Molkenboer-Kuenen JD; Oyen WJ; van der Graaf WT; van Laarhoven HW
Int J Cancer; 2013 Jul; 133(2):307-14. PubMed ID: 23335047
[TBL] [Abstract][Full Text] [Related]
29. Fluorescence-Guided Visualization of Soft-Tissue Sarcomas by Targeting Vascular Endothelial Growth Factor A: A Phase 1 Single-Center Clinical Trial.
Steinkamp PJ; Pranger BK; Li MF; Linssen MD; Voskuil FJ; Been LB; van Leeuwen BL; Suurmeijer AJH; Nagengast WB; Kruijff S; van Ginkel RJ; van Dam GM
J Nucl Med; 2021 Mar; 62(3):342-347. PubMed ID: 32680922
[TBL] [Abstract][Full Text] [Related]
30. 68Ga-TRAP-(RGD)3 Hybrid Imaging for the In Vivo Monitoring of αvß3-Integrin Expression as Biomarker of Anti-Angiogenic Therapy Effects in Experimental Breast Cancer.
Kazmierczak PM; Todica A; Gildehaus FJ; Hirner-Eppeneder H; Brendel M; Eschbach RS; Hellmann M; Nikolaou K; Reiser MF; Wester HJ; Kropf S; Rominger A; Cyran CC
PLoS One; 2016; 11(12):e0168248. PubMed ID: 27992512
[TBL] [Abstract][Full Text] [Related]
31. Feasibility of ex vivo fluorescence imaging of angiogenesis in (non-) culprit human carotid atherosclerotic plaques using bevacizumab-800CW.
Huisman LA; Steinkamp PJ; Hillebrands JL; Zeebregts CJ; Linssen MD; Jorritsma-Smit A; Slart RHJA; van Dam GM; Boersma HH
Sci Rep; 2021 Feb; 11(1):2899. PubMed ID: 33536498
[TBL] [Abstract][Full Text] [Related]
32. Panitumumab-IRDye800CW for Fluorescence-Guided Surgical Resection of Colorectal Cancer.
Marston JC; Kennedy GD; Lapi SE; Hartman YE; Richardson MT; Modi HM; Warram JM
J Surg Res; 2019 Jul; 239():44-51. PubMed ID: 30798171
[TBL] [Abstract][Full Text] [Related]
33. Targeted Dual-Modality Imaging in Renal Cell Carcinoma: An Ex Vivo Kidney Perfusion Study.
Hekman MC; Boerman OC; de Weijert M; Bos DL; Oosterwijk E; Langenhuijsen JF; Mulders PF; Rijpkema M
Clin Cancer Res; 2016 Sep; 22(18):4634-42. PubMed ID: 27103404
[TBL] [Abstract][Full Text] [Related]
34. Phase I trial of intraoperative detection of tumor margins in patients with HER2-positive carcinoma of the breast following administration of 111In-DTPA-trastuzumab Fab fragments.
Holloway CM; Scollard DA; Caldwell CB; Ehrlich L; Kahn HJ; Reilly RM
Nucl Med Biol; 2013 Jul; 40(5):630-7. PubMed ID: 23618841
[TBL] [Abstract][Full Text] [Related]
35. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
36. Fluorescence-guided imaging for resection margin evaluation in head and neck cancer patients using cetuximab-800CW: A quantitative dose-escalation study.
Voskuil FJ; de Jongh SJ; Hooghiemstra WTR; Linssen MD; Steinkamp PJ; de Visscher SAHJ; Schepman KP; Elias SG; Meersma GJ; Jonker PKC; Doff JJ; Jorritsma-Smit A; Nagengast WB; van der Vegt B; Robinson DJ; van Dam GM; Witjes MJH
Theranostics; 2020; 10(9):3994-4005. PubMed ID: 32226534
[TBL] [Abstract][Full Text] [Related]
37. 111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib.
Desar IM; Stillebroer AB; Oosterwijk E; Leenders WP; van Herpen CM; van der Graaf WT; Boerman OC; Mulders PF; Oyen WJ
J Nucl Med; 2010 Nov; 51(11):1707-15. PubMed ID: 20956472
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer.
Yardley DA; Raefsky E; Castillo R; Lahiry A; Locicero R; Thompson D; Shastry M; Burris HA; Hainsworth JD
Clin Breast Cancer; 2011 Oct; 11(5):297-305. PubMed ID: 21729666
[TBL] [Abstract][Full Text] [Related]
39. Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer.
Pentheroudakis G; Kotoula V; Kouvatseas G; Charalambous E; Dionysopoulos D; Zagouri F; Koutras A; Papazisis K; Pectasides D; Samantas E; Dimopoulos MA; Papandreou CN; Fountzilas G
Clin Breast Cancer; 2014 Oct; 14(5):330-8. PubMed ID: 24703319
[TBL] [Abstract][Full Text] [Related]
40. Antiangiogenic antibody improves melanoma detection by fluorescently labeled therapeutic antibodies.
Sweeny L; Prince A; Patel N; Moore LS; Rosenthal EL; Hughley BB; Warram JM
Laryngoscope; 2016 Dec; 126(12):E387-E395. PubMed ID: 27576611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
